Compare OFIX & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | DNA |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | 485 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 455.8M |
| IPO Year | 1998 | N/A |
| Metric | OFIX | DNA |
|---|---|---|
| Price | $12.86 | $7.79 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $17.25 | $8.50 |
| AVG Volume (30 Days) | 228.9K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | N/A |
| Revenue This Year | $6.10 | N/A |
| Revenue Next Year | $6.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $10.25 | $5.37 |
| 52 Week High | $16.99 | $17.58 |
| Indicator | OFIX | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.64 | 58.83 |
| Support Level | $12.33 | $6.26 |
| Resistance Level | $16.38 | $10.06 |
| Average True Range (ATR) | 0.41 | 0.58 |
| MACD | 0.19 | 0.19 |
| Stochastic Oscillator | 88.71 | 91.80 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.